CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Intravenous Immunoglobulin for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: Clinical- and Cost-Effectiveness Analyses

Last updated: March 31, 2009
Result type: Report

CADTH’s timely assessment of interventions for chronic inflammatory demyelinating polyneuropathy (CIDP) compared IVIg with alternative treatments, including corticosteroids and plasma exchange. Questions surrounding the comparative health outcomes and costs of potential treatment options for CIDP and the cost and availability of IVIg highlighted the need for this assessment.

Report

This complete report has been extensively reviewed by external clinical and methodological experts:

Summaries

In support of the CADTH assessment, the following summaries have been developed: